ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2022; 12(17):7645. doi:10.7150/thno.78949 This issue Cite
Erratum
Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway: Erratum
Hui-Juan Liu1,2 
*, Yuan Qin1,2*, Zi-Han Zhao1,2*, Yang Zhang4*, Jia-Huan Yang1,2, Deng-Hui Zhai1,2, Fang Cui1,2, Ce Luo1, Man-Xi Lu1, Piao-Piao Liu1, Heng-Wei Xu1,2, Kun Li1,2, Bo Sun2, Shuang Chen2, Hong-Gang Zhou1 , Cheng Yang1,2 , Tao Sun1,2,3
1. State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, Nankai University, Tianjin, China.
2. Tianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs and Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin, China.
3. Department of Gastroenterology and Hepatology, General Hospital, Tianjin Medical University, Tianjin Institute of Digestive Disease, Tianjin, China.
4. Department of Anesthesiology, Tianjin Fourth Central Hospital, Tianjin, China.
*These authors have contributed equally to this work.
Citation:
Liu HJ, Qin Y, Zhao ZH, Zhang Y, Yang JH, Zhai DH, Cui F, Luo C, Lu MX, Liu PP, Xu HW, Li K, Sun B, Chen S, Zhou HG, Yang C, Sun T. Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway: Erratum. Theranostics 2022; 12(17):7645. doi:10.7150/thno.78949. https://www.thno.org/v12p7645.htm
Other stylesCorrected-article in Theranostics, Volume 10, 9083
The authors apologize that the original version of the above article contains errors that need to be corrected. Incorrect images for Figure 3G were used during figure assembly. The correction does not affect the conclusions of the above paper. The authors sincerely apologize for any inconvenience these errors may have caused. The corrected Figure 3G appears below.
Figure 3G
Corrected figure.
Author contact
Corresponding authors: Tao Sun, E-mail: tao.sunedu.cn; Cheng Yang, E-mail: cheng.yangedu.cn; Hong-gang Zhou, E-mail: honggang.zhouedu.cn; Hui-juan Liu, E-mail: liuhuijuanxyzcom.
Published 2022-11-2
Citation styles
APA
Liu, H.J., Qin, Y., Zhao, Z.H., Zhang, Y., Yang, J.H., Zhai, D.H., Cui, F., Luo, C., Lu, M.X., Liu, P.P., Xu, H.W., Li, K., Sun, B., Chen, S., Zhou, H.G., Yang, C., Sun, T. (2022). Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway: Erratum. Theranostics, 12(17), 7645. https://doi.org/10.7150/thno.78949.
ACS
Liu, H.J.; Qin, Y.; Zhao, Z.H.; Zhang, Y.; Yang, J.H.; Zhai, D.H.; Cui, F.; Luo, C.; Lu, M.X.; Liu, P.P.; Xu, H.W.; Li, K.; Sun, B.; Chen, S.; Zhou, H.G.; Yang, C.; Sun, T. Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway: Erratum. Theranostics 2022, 12 (17), 7645. DOI: 10.7150/thno.78949.
NLM
Liu HJ, Qin Y, Zhao ZH, Zhang Y, Yang JH, Zhai DH, Cui F, Luo C, Lu MX, Liu PP, Xu HW, Li K, Sun B, Chen S, Zhou HG, Yang C, Sun T. Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway: Erratum. Theranostics 2022; 12(17):7645. doi:10.7150/thno.78949. https://www.thno.org/v12p7645.htm
CSE
Liu HJ, Qin Y, Zhao ZH, Zhang Y, Yang JH, Zhai DH, Cui F, Luo C, Lu MX, Liu PP, Xu HW, Li K, Sun B, Chen S, Zhou HG, Yang C, Sun T. 2022. Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway: Erratum. Theranostics. 12(17):7645.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.